{"firstName":"Jaewhan","lastName":"Song","position":"Professor","department":"Department of Biochemistry, Yonsei University","homepages":["http://lts.yonsei.ac.kr/introduction/professor.html"],"homepage":"http://lts.yonsei.ac.kr/introduction/professor.html","orcid":"","googleScholar":"https://scholar.google.com/citations?user=KEa6N28AAAAJ&hl=en","emails":["jso678@yonsei.ac.kr"],"email":"jso678@yonsei.ac.kr","phoneOffice":"81-02-2123-5695","phoneNumbers":[],"phoneLab":"","thumbAlt":"","listDescription":"","listThumbAlt":"","visibility":"public","researchKeywords":["Necroptosis","Ferroptosis","Regulated Cell Death","Cancer Biology","Metabolic Liver Disease"],"researchInterest":["The molecular regulation of regulated cell death including necroptosis, ferroptosis, pyroptosis and their roles in cancer, immune regulation, and metabolic diseases.","Integration of cell biology with animal disease models to identify novel therapeutic targets for treatment-resistant cancers and metabolic liver disorders.","Development and application of genetically engineered mouse models to dissect disease mechanisms and to translate fundamental discoveries in cell death and metabolism into potential therapeutic strategies."],"education":[{"period":"1995-2000","content":"Ph.D. Northwestern University"},{"period":"1993-1995","content":"M.S. Yonsei University"},{"period":"1987-1993","content":"B.S. Yonsei University"}],"career":[{"period":"2010-present","content":"Associate/Professor, Yonsei University"},{"period":"2002-2010","content":"Assistant/Associate Professor, Sungkyunkwan University"},{"period":"2000-2002","content":"Post-doc fellow, Northwestern University"}],"patents":[{"year":"2023","content":"Novel MKRN1 Inhibitor for Metabolic Diseases This patent covers a novel MKRN1 inhibitor, specifically including ebastine as an active ingredient, and its pharmaceutical composition for the prevention or treatment of obesity, diabetes, fatty liver disease, and steatohepatitis. Applicant and assignee: Yonsei University–Industry Foundation. Application No. 10-2023-0023711 (Feb. 22, 2023)."},{"year":"2018","content":"Pharmaceutical Composition for Treating Metabolic Diseases via MKRN1 Inhibition This invention relates to pharmaceutical compositions containing MKRN1 expression or activity inhibitors for the prevention and treatment of metabolic diseases. Korean Patent No. 10-1925020 (Jan. 28, 2018)."},{"year":"2016","content":"Cervical Cancer Prediction and Diagnosis Method Using MKRN1 Expression This patent provides a diagnostic method for predicting and diagnosing cervical cancer based on human papillomavirus (HPV) testing combined with MKRN1 expression patterns. Korean Patent No. 10-1693190 (Feb. 30, 2016)."},{"year":"2015","content":"Regulation of p14ARF Tumor Suppressor by MKRN1 in Gastric Cancer This invention addresses the role of MKRN1 as a post-translational regulator of the p14ARF tumor suppressor gene in gastric cancer. Korean Patent No. 10-1504559 (Mar. 16, 2015)."},{"year":"2015","content":"PPAR-γ Inhibition and Adipocyte Differentiation Suppression by Camptothecin Derivatives This patent describes the PPAR-γ inhibitory activity of camptothecin and its analogs, leading to suppression of adipocyte differentiation, with implications for metabolic disease treatment. Korean Patent No. 10-1576793 (Feb. 7, 2015)."},{"year":"2006","content":"Antiviral Therapeutic Composition Containing Jab1 An early patent covering a therapeutic composition for viral infectious diseases containing Jab1, highlighting antiviral signaling regulation. Korean Patent No. 10-0602146 (July 10, 2006)."}],"awards":[{"period":"2014","content":"Macrogen InC (KSBMB) Best Research Award"},{"period":"2013","content":"Yonsei University, Best Research Award"}]}